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The aim of this study was to evaluate the prognostic value of the promoter methylation status of galanin (GAL) and
galanin receptor 1/2 (GALR1/2) by assessing their association with disease-free survival and known prognostic factors in
head and neck cancer. We generated methylation profiles of GAL and GALR1/2 in tumor samples obtained from 202
patients with head and neck squamous cell carcinoma (HNSCC); these included 43 hypopharynx, 42 larynx, 59 oral cavity,
and 58 oropharynx tumor samples. CpG island hypermethylation status of the three genes was analyzed using
quantitative methylation-specific PCR (Q-MSP). In order to determine the prognostic value of the methylation status of
these genes, the associations between methylation index and various clinical characteristics, especially tumor site, were
assessed for tumors from patients with HNSCC. The methylation index was positively correlated with female gender
(P¼ 0.008) and disease recurrence (P¼0.01) in oral cancer and human papillomavirus (HPV)-positive (P¼0.004) status
and disease recurrence (P¼ 0.005) in oropharyngeal cancer. Among patients with oral and oropharyngeal cancer,
promoter hypermethylation of GAL, GALR1, or GALR2was statistically correlated with a decrease in disease-free survival
(log-rank test, P¼ 0.036 and P¼ 0.042, respectively). Furthermore, methylation of GAL, GALR1, or GALR2 exhibited the
highest association with poor survival (log-rank test, P¼ 0.018) in patients with HPV-negative oropharyngeal cancers. As
such, GAL and GALR1/2 methylation status may serve as an important site-specific biomarker for prediction of clinical
outcome in patients with HNSCC. © 2016 Wiley Periodicals, Inc.
Key words: galanin; GALR1/2; hypermethylation; oral and oropharyngeal cancer; HPV
INTRODUCTION
Head and neck squamous cell carcinomas
(HNSCCs) constitute an anatomically heterogeneous
group of solid tumors arising from the nasopharynx,
oral cavity, oropharynx,hypopharynx, and larynx [1].
In addition, HNSCC is a highly heterogeneous disease
that develops via one of two primary routes: chemical
carcinogenesis through exposure to tobacco and
alcohol or virally induced tumorigenesis [2,3]. Over
the last few decades, there has been a decline in
carcinomas of the hypopharynx and larynx [4]. In
contrast to this trend, the incidence of oropharynx
squamous cell carcinomas (OPSCCs) has increased
over the last couple of decades [5]. Human papillo-
mavirus (HPV)-associated OPSCCs represent distinct
disease entities in terms of their epidemiology,
biology, and clinical behavior relative to their
tobacco-associated counterparts [6]. Therefore, mo-
lecular classification of HNSCCs is required to provide
prognostic as well as mechanistic information to
improve patient care.
Aberrant promoter methylation, an important
hallmark of cancer cells, is considered a major
mechanism underlying the inactivation of tumor-
related genes. Several studies have reported that
promoter methylation of tumor suppressor genes
represents a common mechanism of transcriptional
silencing in HNSCC [3]. Aberrant methylation in
several tumor suppressor genes has been demon-
strated to be involved in the development and
progression of HNSCC and has been used as a
biomarker to definitively predict disease outcome
[7]. Numerous epigenetic events in carcinogenic
pathways have been studied recently, resulting in
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the development ofmethods for detectingCpG island
promoter methylation patterns to stratify high-risk
groups among patients with HNSCC. Choudhury
reported that promoter methylation of DAPK, p16,
RASSF1, and MINT31 is significantly associated with
HPV (þ) tumors of HNSCC [8]. Promoter hyper-
methylation of DAPK and p16 is significantly associ-
ated with smoking status and may be used to predict
the risk of incidence of HNSCC [9]. The degree of
global hypomethylation in HNSCC is associated with
smoking history, alcohol consumption, and tumor
stage [10].
Our recent efforts to determine the methylation
profiles ofGAL andGALR1/2were insufficient because
of the small sample size studied and lack of
discrimination between the sites of origin of primary
tumors [11,12]. However, it is likely that the galanin
system plays a dominant role in tumorigenesis in
HNSCC. G protein-coupled receptors (GPCRs) modu-
late multiple intracellular signaling transduction
pathways and elicit cytostatic and/ or cytotoxic
effects, which include cell cycle arrest and apopto-
sis [13]. Furthermore, epigenetic repression of GPCR
expression is related to prognosis and the response to
radiotherapy/chemotherapy [14]. Although previous
studies have revealed a correlation between high-
methylation tumors and decreased survival, this
finding requires external validation along with site-
specific analysis.
The aim of this study was to determine the
methylation status of GAL, GALR1, and GALR2 in
HNSCC to evaluate their clinical significance as
prognostic biomarkers for recurrence risk and sur-
vival. We attempted to determine whether HNSCC
primary tumors originating from different anatomic
sites (hypopharynx, larynx, oral cavity, and orophar-
ynx) exhibited similar DNA methylation changes, or
whether DNAmethylation events were specific to the
anatomic site.
RESULTS
Analysis of Methylation Status of GAL and
GALR1/2 Genes
Q-MSP was used to assess the aberrant promoter
methylation status of GAL, GALR1, and GALR2 in
tumors from the hypopharynx (n¼43), larynx
(n¼42), oral cavity (n¼59), or oropharynx (n¼58).
GAL was methylated in 5 (11.6%), GALR1 in 19
(44.2%), and GALR2 in 13 (28.6%) of the 43
hypopharyngeal cancers examined. In laryngeal
cancers, the frequency of hypermethylation was
23.8% for GAL, 59.5% for GALR1, and 40.5% for
GALR2. The frequency of promoter methylation was
detected to be 19.0% for GAL, 60.3% for GALR1, and
32.8% for GALR2 in oropharyngeal cancers. Among
59 cases with oral cancers, the frequency of hyper-
methylation was 20.3% for GAL, 40.7% for GALR1,
and 45.8% for GALR2 (Figure 1A). Analysis of the 43
hypopharyngeal samples revealed that at least one of
these three genes was methylated in 18 (65.1%)
primary tumors (Figure 1B). The frequency of meth-
ylation of at least one gene was increased in laryngeal
cancers (66.7%) (Figure 1C), oral cancers (59.3%)
(Figure 1D), and oropharyngeal cancers (70.7%)
(Figure 1E). Matched pairs of head and neck tumors
and adjacent normal mucosal tissues were obtained
from surgical specimens collected from67 patients for
initial methylation screening. We have added these
data as Supplementary Table S2.
Correlation Between GAL and GALR1/2 Methylation
and Clinicopathological Assessment
Characteristics and clinicopathologic features of
patients, including age at diagnosis, sex, alcohol
consumption, smoking habit, tumor staging, HPV
status, and tumor recurrence, are summarized in
Table 1. Methylation index (MI) was defined as the
ratio between the number of methylated genes and
the total number of tested genes in each sample. The
mean differences in MI according to the age of onset,
sex, alcohol consumption, smoking habit, tumor size,
lymph node status, clinical stage, HPV status, and
recurrence are illustrated in Figure 2. In particular, in
hypopharyngeal cancers, MI was significantly higher
in male (0.980.77) than in female (0.290.49;
P¼0.030) patients (Figure 2A). There was no signifi-
cant association between clinicopathologic character-
istics in 35 laryngeal cancer patients (Figure 2B). HPV-
positive oropharyngeal cancers show an affinity for
the oropharynx (27/58; 46.6%). Among oral cancers,
MI was significantly higher in female (1.751.06)
than in male (0.890.94; P¼0.001) patients, as well
as recurrence-positive cases (1.51.06) relative to
recurrence-negative cases (0.810.91; P¼0.010)
(Figure 2C). Notably, we found that MI was signifi-
cantly higher in HPV-positive than in HPV-negative
cases (1.480.64 vs. 0.811.05; P¼0.005), as well as
in recurrence-positive cases (1.600.88) relative to
recurrence-negative cases (0.870.87; P¼0.004)
(Figure 2D) of oropharyngeal cancers.
Kaplan–Meier Estimates
Kaplan–Meier plots indicated that the methylation
status of GAL and GALR1/2 was related to disease-free
survival (DFS) (Figure 3A–D). Among 43 patients with
hypopharyngeal cancers, the rate of DFS in those with
anymethylated genes was 19.3% (mean survival time;
27.0 months) compared with 38.1% (mean survival
time; 31.2 months) in the group with no methylated
genes (log-rank test, P¼0.744) (Figure 3A). Among the
patients with laryngeal cancers, the rate of DFS of
patients exhibiting methylation of one or more of the
three genes was 24.6% (mean survival time; 27.8
months), compared with 68.6% (mean survival time;
41.6 months) in the group with no methylated genes
(log-rank test,P¼0.265) (Figure3B).Among59casesof
oral cancers, the rate of DFS was lower in the
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Figure 1. Summary of the promoter methylation status of
GAL, GALR1, and GALR2 in 202 HNSCC samples. (A) Compari-
son of rate of methylation status of the promoters of three
genes (GAL, GALR1, and GALR2) in patients with hypophar-
yngeal cancer; blue box, laryngeal cancer; red box, oral cancer;
purple box, oropharyngeal cancer; green box. (B) Distribution of
GAL, GALR1, and GALR2 promoter methylation in hypophar-
yngeal cancer: the promoters of all three genes were hyper-
methylated in 2% (1 of 43) of the tumors, those of two genes
were hypermethylated in 16% (7 of 43) of the tumors, and
those of one gene were hypermethylated in 47% (20 of 43) of
the tumors. None of the genes exhibited hypermethylation in
35% (35 of 43) of the tumors. (C) Hypermethylation status of
genes in tumors from patients with laryngeal cancer (N¼ 42);
(D) hypermethylation status of genes in tumors from patients
with oral cancer (N¼ 58); and (E) hypermethylation status of
genes in tumors from patients with oropharyngeal cancer
(N¼ 59).
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any-methylated genes group than in the no-methyl-
ated genes group (36.7% vs. 76.1%, respectively; log-
rank test, P¼0.035) (Figure 3C). Among patients with
oropharyngeal cancers, theDFS rates for thosewith no
methylated genes and any methylated genes were
85.7% (mean survival time; 22.7 months) and 25.6%
(mean survival time; 19.7 months), respectively (log-
rank test, P¼0.042) (Figure 3D). We did not observe
anycorrelationbetweenmortalityandHPVstatus (log-
rank test, P¼0.826) in the cohort of patients with
oropharyngeal cancer (Figure 4A). Overall survival
tended to be better in HPV-positive patients than in
HPV-negative individuals; however, this was not
statistically significant (87.1% vs. 53.5%, log-rank
test, P¼0.156) (data not shown). However, hyper-
methylation of any of the three investigated geneswas
significantly associated with shortened survival in
HPV- negative patients (log-rank test, P¼0.018)
(Figure 4B).
Prognostic Value of GAL and GALR1/2 Promoter
Hypermethylation
The odds of recurrence associatedwithmethylation
of GAL and GALR1/2 were estimated by multivariate
logistic-regression analysis (Figure 5A–D). When GAL
was methylated in laryngeal cancers, the adjusted
odds ratio for recurrence was 16.5 (95% confidence
interval [CI], 1.84–148.29; P¼0.012) (Figure 5B). In
patients with oral cancers, concomitant methylation
of the gene pair GAL and GALR1 and the gene pair
GALR1 and GALR2 was associated with an odds ratio
for recurrence of 5.45 (95%CI, 1.48–20.1; P¼0.011)
and 4.86 (95%CI, 1.26–18.7; P¼0.021), respectively
(Figure 5C). Notably, patients with oropharyngeal
cancers that exhibited methylation of GALR2 and the
gene pair GAL and GALR2 had a significantly higher
odds ratio for recurrence of 4.84 (95%CI, 1.34–17.53;
P¼0.016) and 6.58 (95%CI, 1.67–25.89; P¼0.007),
respectively (Figure 5D).
Additional analysis of the 42patientswith laryngeal
cancer revealed that those with patients with un-
methylated GAL showed significantly better DFS in
comparison to those with methylated GAL (log-rank
test, P¼0.021) (Supplemental Figure S1A). In oral
cancers, GALR1 promoter hypermethylation was
statistically correlated with a decrease in DFS (log-
rank test, P¼0.008) (Supplemental Figure S1B). A
trend toward poorer DFS was observed in patients
Table 1. Clinical Characteristics of Recruited Head and Neck Cancer Patients
Patient and tumor
characteristics
Hypopharygx
(n¼43) (%)
Larynx
(n¼ 42) (%)
Oral cavity
(n¼59) (%)
Oropharyx
(n¼ 58) (%)
Age
70 and older 16 (37) 13 (31) 14 (24) 18 (31)
Under 70 27 (63) 29 (69) 45 (76) 40 (69)
Gender
Male 36 (84) 41 (98) 47 (80) 47 (81)
Female 7 (16) 1 (2) 12 (20) 11 (19)
Alcohol exposure
Ever 36 (84) 33 (79) 39 (66) 41 (71)
Never 7 (16) 9 (21) 20 (34) 17 (29)
Smoking status
Smoker 33 (77) 31 (74) 45 (76) 40 (69)
Non smoker 10 (23) 11 (26) 14 (24) 18 (31)
Tumor size
T1 1 (2) 6 (14) 11 (19) 11 (19)
T2 19 (44) 6 (14) 30 (50) 22 (38)
T3 9 (21) 9 (22) 4 (7) 6 (10)
T4 14 (33) 21 (50) 14 (24) 19 (33)
Lympho-node status
N0 12 (28) 21 (50) 31 (53) 23 (40)
Nþ 31 (72) 21 (50) 28 (47) 35 (60)
Stage
I 0 (0) 6 (14) 8 (14) 7 (12)
II 8 (19) 3 (7) 16 (27) 10 (17)
III 8 (19) 8 (19) 10 (17) 6 (10)
IV 27 (62) 25 (60) 25 (42) 35 (60)
HPV status
Positive – – 2 (3) 27 (47)
Negative – – 57 (97) 31 (53)
Recurrence events
Positive 21 17 (40) 22 (37) 20 (34)
Negative 22 25 (60) 37 (63) 38 (66)
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with oropharyngeal cancers that exhibited methyla-
tion of the GALR2 promoter (log-rank test, P¼0.052)
(Supplemental Figure S1C).
External Validation of Results From the TCGA Database
The validation of TCGA data for GAL and GALR1/2
methylation in HNSCC and its correlation in cervical
squamous cell carcinoma and endocervical adenocar-
cinoma (CESC) cohorts are shown in Figure S2.
Interestingly, GALmethylation demonstrated an aver-
age b-value of 0.328 in the oropharyngeal SCC TCGA
cohort and 0.275 in the TCGA CESC subset (Supple-
mental Figure S2A). The b-value for methylation of
GALR1 was identified in 0.451 in the oropharyngeal
SCC TCGA cohort and 0.546 in CESC samples
(Supplemental Figure S2B). The b-value of GALR2 was
significantly higher inCESC than in the other HNSCCs
(P<0.001, Student’s t-test) (Supplemental Figure S2C).
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Figure 2. Association betweenmethylation indices (MI) and selected
clinical parameters. The meanMI for the various groups was compared
using Student's t-tests. Association between MI and selected
epidemiologic and clinical characteristics (A) hypopharyngeal cancer:
statistically significant differences were found for the associations
between MI and sex; (B) laryngeal cancer: no differences were noted
with regard to any of the clinical characteristics; (C) oral cancer:
statistically significant differences were found for the associations
between MI and sex and MI and recurrence status (positive vs.
negative); (D) oropharyngeal cancer: statistically significant differences
were found for the associations between MI and HPV status (positive
vs. negative) and between MI and recurrence status (positive vs.
negative). Means and standard deviations are also indicated, and
statistical comparisons between groups are depicted. A probability of
<0.05 (P< 0.05) was considered to represent a statistically significant
difference.
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DISCUSSION
The identification of epigenetic modifications of
GAL, GALR1, and GALR2 genes is important for the
elucidation of mechanisms underlying tumorigenesis
and for the assessment of recurrence risk in patients.
Here, we reported a real-time PCR analysis of DNA
methylation profiles in genomic DNA from 202
HNSCC tissues derived from cancers originating in
four anatomic sites. Overall, we found that aberrant
promoter methylation patterns of GAL and GALR1/2
in primary tumors are indicators of an increased risk
of recurrence in patients with oral and oropharyngeal
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Figure 3. Kaplan–Meier survival curves forpatientswithHNSCCaccording toGAL,GALR1, andGALR2methylation
status. (A) Methylation status in patients with hypopharyngeal cancer (n¼ 43; P¼ 0.744). (B) Methylation status in
patients with laryngeal cancer (n¼ 42; P¼ 0.265). (C) Methylation status in patients with oral cancer (n¼ 59;
P¼ 0.036). (D) Methylation status in patients with oropharyngeal cancer (n¼ 58; P¼ 0.042).
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Figure 4. Kaplan–Meier survival curves for patients with oropharyngeal cancer according to HPV status and
methylation status. (A) HPV status of patients with oropharyngeal cancer (n¼ 58; P¼ 0.826); HPV(þ), HPV positive;
HPV(), HPV negative. (B) Combined analyses of HPV status and GAL, GALR1, and GALR2 methylation status
(P¼ 0.018); Me, methylation; Um, unmethylation.
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cancer. The features of DNA methylation are loci-
related, site-specific, as well as correlated with the
HPV status of the patient.
Exposure to several carcinogens, such as HPV,
tobacco, and alcohol, has been associated with
epigenetic gene inactivation in human cancers, for
example, those of the head and neck, esophagus, and
lung [15,16]. Recently, oncogenic viruses such as HPV
and EBV have been shown to evoke cancerous
changes to the DNA methylome of the cell by
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Figure 5. Odds ratios for recurrence based on the multivariate logistic-regression model adjusted for age (70 yr
and older vs.<70 yr), sex, smoking status, alcohol exposure, and tumor stage (I–IV). Multivariate logistic-regression
analysis revealed the estimated odds of recurrence associated with GAL, GALR1, and GALR2 methylation;
P< 0.05. (A)Multivariate logistic regression analysis for hypopharyngeal cancer; (B) multivariate logistic regression
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regression analysis for oropharyngeal cancer.
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increasing activity of DNA methyltransferases
(DNMTs), enzymes that methylate the DNA of the
host genome as part of the tumorigenic path-
way [17,18]. Promoter hypermethylation studies
have largely identified only a limited number of
candidate genes in HNSCC [1]. Therefore, the
development of an integrated analysis method,
applicable to various tumor types, is necessary for
the discovery of correlation between the tumor
primary site and tumor-specific characteristics. Inter-
estingly, we found a strong association between GAL
and GALR1/2 methylation levels and gender in
hypopharyngeal and oral cancers; however, GAL
and GALR1/2 methylation levels were not associated
with gender in laryngeal and oropharyngeal cancers.
Female gender is positively correlated with methyla-
tion for some genes, including MTAP, in gastric
cancer [19], CDH1 in lung cancer tissue [20], and p14
in colorectal cancer [21]. The activity of sex hormones
may be mediated via gene-specific epigenetic
modifications [22].
GPCRs are the largest signal-conveying receptor
family that mediate multiple physiological processes;
however, their role in tumor biology is poorly
understood [19]. Various studies suggest that possess
potent antitumor effects and neuropeptides function
as tumor suppressor genes in human cancers. Hyper-
methylation of the tachykinin-1 (TAC1) gene is
related with poor prognosis in patients with head
and neck, colon, and esophageal cancer [20–22]. The
promoter methylation profiles of the TAC1 and
tachykinin receptor 1-encoding gene appear to
represent significant markers of outcome in patients
with head and neck cancer [20]. In addition,
somatostatin promoter hypermethylation is a com-
mon event in human colon cancer [22]. Simultaneous
analyses of the methylation status of multiple tumor
suppressor genes are important for predictions of
tumorigenesis, biological behavior, and the develop-
ment of future targeted therapy.
GAL, a 30-amino acid peptide in humans, has been
shown to act as a highly specific and efficient
pharmaceutical agent in vivo; GAL targets the galanin
system via its cognate receptors GALR1, GALR2, and
GALR3 [23]. The identification ofGALR1methylation
in DNA obtained from postmenopausal women
indicates the presence of endometrial malig-
nancy [24]. Hypermethylation of GALR2 has been
reported in several cancers such as colorectal can-
cer [25] and breast cancer [26], as well as in
hepatocellular tumorigenesis [27]. The silencing
function of either GAL or GALR1 induces the
apoptosis of both drug-sensitive and drug-resistant
cells and synergistically enhances the effect of
chemotherapy (5-FU and oxaliplatin) in colorectal
cancer [28]. Furthermore, GALR2-overexpressing co-
lorectal cancer cells are more susceptible to bevaci-
zumab than control cells, and exogenous GALR2
expression results in the apoptosis of neuroblastoma
cells [29,30]. Therefore, our understanding of the
functions ofGAL andGALR1/2with respect toHNSCC
is improving.
A previous study in our laboratory reported the
function of the GALR1/2 signaling pathways in
HNSCC [14]. Importantly, the activation of the
GALR1 signaling pathway suppresses tumor cell
growth via phosphorylation of extracellular signal-
regulated kinase 1/2 (ERK1/2), which is related to the
downregulation of cyclin D1 and the upregulation of
cyclin-dependent kinase inhibitors [31]. The reduc-
tion of HNSCC cell growth in response to GALR2
expression in the presence of galanin is due to the
induction of apoptosis. GALR2-mediated apoptosis is
caspase-independent and involves the downregula-
tion of ERK1/2 and the induction of the pro-apoptotic
Bcl-2 protein Bim [32].While the functionofGALR3 is
not fully known, GALR3-expressing cells show acti-
vation of the PI3K pathway [33]. TheGALR3 promoter
region is CþG-rich; however, the degree of conden-
sation of CpG sequences in this region is low [34].
Therefore, the role of GALR3 differs from that of
GALR1 and GALR2 [31]. The differing signal trans-
duction pathways related to each galanin receptor
might account for their different biological activities
in various types of cancer [35]; therefore, the effect of
galanin signaling is likely to be dependent on the
expression level of each receptor, and to occur in a cell
type-specific manner. Significantly, the different
methylation patterns of these three genes in primary
tumors may be utilized as the basis for identification
of patients with an increased risk of recurrence.
A study of this type involving human specimens
and utilizing high-throughput profiling platforms
may be susceptible to measurement bias from a
variety of sources. First, numerous genes have been
reported as individual biomarkers for prognosis in
HNSCC. The present study provides evidence that the
methylation status of GAL, GALR1, and GALR2
represents an independent prognostic factor for DFS
in patients with oral cancers and HPV-negative
oropharyngeal cancers. Further investigations
showed the aberrant methylation of GAL may be of
potential use as a marker for patients with laryngeal
cancer that are at a high risk of relapse. Biomarker
discovery for HPV-negative HNSCC is crucial for the
improvement of patient outcomes. Simultaneous
analyses of the methylation status of multiple tumor
suppressor genes are important for predictions of
tumorigenesis and biological behavior as well as for
the development of targeted therapy. Our findings
suggest that such methylation markers could be used
in clinical practice to distinguish patients that may
benefit from adjuvant therapy after initial surgical
treatment; however, additional prospective studies
are required to validate these genes in other groups of
patients with HNSCC.
In conclusion, GAL and GALR1/2 genes were
identified as aberrantly methylated in HNSCC
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patients. Importantly, the methylation patterns of
these three genes in primary tumors may be used to
identify patients with oral and oropharyngeal cancers
that are at a higher risk of recurrence. These findings
should benefit oral and oropharyngeal cancer screen-
ing and surveillance programs. The differences in
promoter methylation patterns observed between
HPV-positive and HPV-negative tumors, and their
effects on downstream signaling pathways involved
in carcinogenesis, provide several testable hypotheses
for further research.
MATERIALS AND METHODS
Tumor Samples
Two hundred and two primary HNSCC samples
were obtained from patients during surgery at the
Department of Otolaryngology, Hamamatsu Univer-
sity School of Medicine. All patients provided written
informed consent and the study protocol was
approved by the Institutional Review Board of the
Hamamatsu University School of Medicine. Clinical
information, including age, sex, tumor site, smoking
habit, alcohol consumption, tumor size, lymph node
status, and stage grouping were obtained from the
patients’ clinical records. Themale/female ratio of the
patients was 171:31. The mean age was 64.9 yr
(range¼36–90). Primary tumors were located in the
hypopharynx (n¼43), larynx (n¼42), oral cavity
(n¼59), or oropharynx (n¼58).
Bisulfite Treatment and Quantitative Methylation-Specific
PCR Analysis
Genomic DNA was extracted using the Methyl-
Easy Xceed Rapid DNA Bisulfite Modification Kit
(TaKaRa, Tokyo, Japan) and subjected to bisulfite
conversion, as previously described [11]. The meth-
ylation status of the CpG islands in the promoter
region of GAL and GALR1/2 was determined in 202
primary HNSCC samples and 67 noncancerous
mucosal samples. Promoter methylation levels of
GAL and GALR1/2 were determined using quantita-
tive methylation-specific PCR (Q-MSP) with the
TaKaRa Thermal Cycler Dice TM Real Time System
TP800 (TaKaRa). The primer sequences are listed in
Supplemental Table S1. A standard curve was
established using serial dilutions of EpiScopeTM
Methylated HeLa gDNA (TaKaRa). The normalized
methylation value (NMV) was determined as fol-
lows: NMV¼ (Target gene-S/Target gene-FM)/
(ACTB-S/ACTB-FM), where Target gene-S and Target
gene-FM represent target gene methylation levels in
the sample and universal methylated DNA, respec-
tively, and ACTB-S and ACTB-FM correspond to
b-actin in the sample and universal methylated
DNA, respectively. Analysis was performed using the
Thermal Cycler Dice Real Time System TP800
Software Ver. 1.03A (TaKaRa), according to the
manufacturer’s directions for use [12].
Analysis of High-Risk HPV Status
The HPV status was evaluated using the HPV
Typing Set (Takara Bio., Tokyo, Japan), a PCR primer
set specifically designed to identify HPV genotypes
16, 18, 31, 33, 35, 52, and 58 in genomic
DNA. The PCR HPV Typing Set method was
performed according to the manufacturer’s proto-
col. The PCR products were separated using 9%
polyacrylamide gel electrophoresis and stained with
ethidium bromide.
Collection of Publicly Available Data From The Cancer
Genome Atlas (TCGA)
Aberrant DNA methylation data for a total of 522
HNSCC cases, comprising 10 hypopharynx cases, 116
larynx cases, 325 oral cavity cases, 71 oropharynx
cases, and 303CESC cases (TCGApublic data available
in March 2016), were collected from the TCGA data
portal (https://tcga-data.nci.nih.gov/tcga). DNA
methylation data obtained using the Infinium Hu-
manMethylation450 platform (Illumina, Inc., San
Diego, CA) were shown as the b-value.
Statistical Analysis
Statistical analysis for the association of variables
was performed using Student’s t-test. The disease-free
time was measured from the date of the initial
treatment to the date of diagnosis of locoregional
recurrence or distant metastasis. The Kaplan–Meier
test was used to calculate the survival probability, and
the log-rank test was used to compare the difference
between survival rates. Multivariate logistic regres-
sion analysis involving stage grouping, age, sex,
alcohol intake, smoking status, andDNAmethylation
status was used to identify the predictive value of the
prognostic factors [36]. Differences with P<0.05 were
considered significant. All statistical analyses were
performed using StatMate IV (ATMS Co., Ltd., Tokyo,
Japan).
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